Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.

Scientific reports - 25 Jan 2026

Fukuda Yoshiko, Sakurada Yoichi, Kotoda Yumi, Kikushima Wataru, Kashiwagi Kenji

Abstract excerpt

Brolucizumab is a second-generation vascular endothelial growth factor (VEGF) inhibitor. To date, there have been no reports comparing treatment outcomes between exudative age-related macular degeneration with or without the pachychoroid phenotype using a second-generation VEGF inhibitor. The present study compared two-year as-needed brolucizumab treatment outcomes in patients with and without pachychoroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Intravitreal Injections

Share to Macular Degeneration

Share to Treatment Outcome

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 41582270
DOI: 10.1038/s41598-026-37591-y
PMCID: PMC12905284

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.PMID 41582270Read ↗

The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity Read ↗

Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from TaiwanSemantic proximity Read ↗

Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre ExperienceSemantic proximity Read ↗

Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMDSemantic proximity Read ↗

Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Semantic proximity Read ↗

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Phenotype Characteristics of Fellow Eyes in Patients With Early Onset of Neovascular Age-Related Macular Degeneration.Semantic proximity Read ↗

Qualitative analysis by OCTA in patients with choroidal neovascularization secondary to angioid streaks as predictors of disease recurrences over timeSemantic proximity Read ↗

Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesSemantic proximity Read ↗

Phenotype and Outcomes of Phakic Versus Pseudophakic Primary Rhegmatogenous Retinal Detachments: Cataract or Cataract Surgery Related?Semantic proximity Read ↗

Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialistsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.